Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis Must Divest Estorra Rights For FTC Green Light On Sanofi Merger

This article was originally published in The Pink Sheet Daily

Executive Summary

Aventis has 90 days to sell rights to the insomnia agent back to Sepracor or another buyer approved by the Federal Trade Commission. The agency says Estorra would overlap with Sanofi’s Ambien.
Advertisement

Related Content

Quintiles Restructures Early Development/Lab Services Division
Quintiles Restructures Early Development/Lab Services Division
Aventis’ Estorra Rights Acquired By Private Equity Firm For $115 Mil.
Aventis’ Estorra Rights Acquired By Private Equity Firm For $115 Mil.
Aventis Launching Ketek With 1,800-Person Primary Care Sales Force
Aventis Launching Ketek With 1,800-Person Primary Care Sales Force
Sanofi Expects Aventis Merger To Close By End Of July
Sepracor/Aventis Agreement Would Aid Estorra Filings Outside The U.S.
Sepracor/Aventis Agreement Would Aid Estorra Filings Outside The U.S.
Sanofi-Aventis Merger Clears Hurdle: Pfizer To Buy Aventis' Camptosar Rights For $620 Mil.

Topics

Advertisement
UsernamePublicRestriction

Register

PS060151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel